Costas Lallas, MDD
Immunotherapy for patients with genitourinary malignancies is no longer the domain of oncologists.
at the 2017 American Urological Association, Lallas, a professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discussed the current role of immunotherapy for patients with genitourinary cancers, the potential for immunotherapy in combination with chemotherapy, and how the rise of immunotherapy affects all providers treating patients with these malignancies.
OncLive: Can you give an overview of your presentation?
The course was targeted toward advanced practice providers. With multidisciplinary care and interdisciplinary conferences, we are seeing these patients more and more. Some of the medications that we talked about aren't necessarily medications that we administer ourselves. However, because we are seeing these patients and we're involved in their care all the way through, this is something that we need to familiarize ourselves with, not only for efficacy but also for side effects. With the work force shortages, there are not enough urologists to see patients, so many of these patients are being seen by advanced practice providers.
Due to multidisciplinary care and work force shortages, many of our patients are being seen by advanced practice providers making it important for everyone to understand the chemotherapy and immunotherapy regimens for genitourinary malignancies.
What is the status of regimens combining chemotherapy and immunotherapy?
Historically, combinations with chemotherapy has been the goal but it depends on the tumor type. In the presentation, we discussed different tumor types including prostate cancer, kidney cancer, testicular cancer, and urothelial cancer; which includes bladder cancer and upper tract urothelial cancer.
... to read the full story